New prospects in non-small cell lung cancer treatment: Pharmacogenomics;Nuevas perspectivas en el tratamiento del cáncer de pulmón no microcítico: Farmacogenómica

Oncologia

Volumn 29, Issue 2, 2006, Pages 55-64

  Cobo Dols, M ^a   Gil Calle, S ^a   Villar Chamorro, E ^a   Ales Diaz I ^a   Montesa Pino, A ^a   Alcaide Garcia J ^a   Gutierrez Calderon V ^a   Carabante Ocon F ^a   Breton Garcia J J ^a   Benavides Orgaz, M ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Chemotherapy; Non small cell lung cancer; Pharmacogenomics

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; IRINOTECAN; NAVELBINE; TAXANE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENETIC TRAIT; GENETIC TRANSCRIPTION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; PHARMACOGENOMICS; REVIEW; TREATMENT OUTCOME;

EID: 33744749582     PISSN: 03784835     EISSN: 03784835     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Parkin DM. Internacional variation. Oncogene 2004; 23: 6329-6340.
2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899-909.
3. Schiller JH, Harrington D, Belani C, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98.
4. Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish lung cancer group phase III randomized trial. J Clin Oncol 2003; 21:3207-3213.
5. Smit EF, Van Meerbeeck JPAM, Lianes P, et al. Three-arm randomized study of two cisplatin - based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group- EORTC 08975. J Clin Oncol 2003;21:3909-3917.
6. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291.
7. Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001 May 12;357(9267):1478-84
8. Isla D, Lastra R, Aguirre E, Ortega E, Lambea J, Andrés R. Abordaje terapéutico del carcinoma de pulmón no microcítico avanzado: ¿Estamos "avanzando"?. Oncología 2005; 28 (7): 311 -320.
9. Booton R, Thatcher N. Chemotherapy in advanced non small cell lung cancer: indication, intensity and duration. Curr Opin Oncol. 2002;14(2):191-8.
10. Sarries C, Haura EB, Roig B, et al. Pharmacogenomics strategies for developing customized chemotherapy in non-small cell lung cancer. Pharmacogenomics 2002;3:763-780.
11. Lynch TJ, Bell DW, Sordilla R, et al. Activating mutations in the epidermal groth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
12. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
13. Pao W, Miller V, Zukowski M, et al. EGF receptor gene mutations are common in lung cancer from "never smokers" are associated with sensitivity of tumors to gefitinib and erlotinib. PNAS 2004; 101: 13306-13311.
14. Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with gefitinib response in chemorefractary lung adenocarcinomas. Clin Cancer Res 2005 (in press).
15. Rosell R, Tarón M, Ariza A, et al. Molecular predictors of response to chemotherapy in Lung Cancer. Sem Oncol 2004;31:20-27.
16. Siddik ZH. Mechanisms of action of cancer chemotherapeutic agents: DNA interactive alkylaating agents and anti-tumour platinum-base drugs. In: aliso MR, ed. The Cancer Handbook. London. England: Nature Publishing Group; 2002:1295-1313.
17. Schellens JHM, Ma J, Planting ASTh, et al. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 1996;73:1569-1575.
18. Blommaert FA, Charulla M, Terheggen P MAB, et al. Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response. Cancer Res 1993;53:5669-5675.
19. Schaake-Koning C, Van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-530.
20. Van de Vaart PJM, Belderbos J, De Jong D, et al. DNA-adducts levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 2000;89:160-166.
21. Furuta T, Ueda T, Aune G, et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002;62:4899-4902.
22. Conforti G, Mazur SJ, Essigmann JM, et al. Inhibition de RNA polymerase II transcription in human cell extracts by cisplatin DNA damage. Biochemistry 1999;38:6204-6212.
23. Bosken CH, Wei Q, Amos CI, et al. An analysis of DNA repair as a determinant of survival in patients with non-small cell lung cancer. J Natl Cancer Inst 2002; 94: 1091-1099.
24. Rosell R, Lord RVN, Taron M, Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 2002;38:217-227.
25. Rosell R, Crino L, Danenberg K, et al. Targeted therapy in combination with gemcitabine in non-small-cell lung cancer. Sem Oncol 2003;30:19-25.
26. Sarries C, Haura EB, Roig B, Taron M, Abad A, Scagliotti G, Rosell R. Pharmacogenomic strategies for developing customized chemotherapy in non-small-cell lung cancer. Pharmacogenomics 2003;3:763-780.
27. Rosell R, Taron M, Alberola V, Massuti B, Felip E. Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer 2003;41:S97-S102.
28. Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C, Roig B. Nucleotide excision repair pathways involved in cisplatin resistance in non-small cell lung cancer. Cancer Control 2003;10:297-305.
29. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidilate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluoracil chemotherapy. J Clin Oncol 1998;16:309-16.
30. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidilate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19:4298-304.
31. Lord RVN, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8: 2286-2291.
32. Vogel U, Moller P, Dragsted L, et al. Inter.-individual variation, seasonal variation and close correlation of OGG1 and ERCC1 mRNA levels in full blood from healthy volunteers. Carcinogenesis 2002;23:1505-9
33. Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polimorfism in lung cancer patients. Cancer Res 2001;61:1354-7.
34. Taron et al. Proc. ASCO, May 2002 - abstract 1322.
35. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 2002; 20: 4285-4291.
36. Rosell R, Scagliotti G, Danenberg KD, et al. Transcripts in pretreatment biopsias from a three arm randomized trial in metastatic non-small cell lung cancer. Oncogene 2003; 22: 3548-3553.
37. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase Messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004; 10: 1318-1325.
38. Rosell R, Felip E, Taron M. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB nos-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res;2004;10:4215-4219.
39. Kennedy RD, Quinn JE, Johnston PG and Harkin DP. BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 2002;360:1007-1014.
40. Mullan PB, Quinn JE, Gilmore PM, McWilliams S, Andrews H, Gervin C, McCabe N, McKenna S, White P, Song YH, et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001;20:6123-6131.
41. Kennedy RD, Quinn JE, Mullan PB, et al. The role of BRCA1 in the celular response to chemotherapy. J Natl Cancer Inst 2004; 96: 1659-1668.
42. Lafarge S, Sylvain V, Ferrara M, et al. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001; 20: 6597-6606.
43. Mullan PB, Quinn JE, Gilmore PM, et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001; 20: 6123-6131.
44. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63: 6221-6228.
45. Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004; 13: 2443-2449.
46. Gurubhagavatula S, Liu G, Park S, et al. XPD and ARCC1 genetic polimorphimss are prognostic factors in advanced non-small cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22(13):2594- 2601.
47. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncology 2003;4:351-358
48. Chan TA, Hermeneking H, Langauer C, et al. 14-3-3 is required to prevent mitotic catastrophe after DNA damage. Nature 1999;401:616-20
49. ..CpG island hypermetylation in human cancers. Cancer Res 2000;60:4353-4357.
50. Mizuno K, Osada H, Konishi H, et al. Aberrant hypermetylation of the CHRF prophase checkpoint gene in human lung cancer. Oncogene 2002;21:2328-2333